OTCMKTS:RSLSD ReShape Lifesciences (RSLSD) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free RSLSD Stock Alerts $5.37 +0.12 (+2.29%) (As of 12/9/2019) Add Compare Share Share Today's Range$4.55▼$5.3750-Day Range N/A52-Week Range$2.91▼$82.80Volume6,500 shsAverage Volume1,362 shsMarket Capitalization$1.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get ReShape Lifesciences alerts: Email Address Ad Stansberry ResearchHow to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."Get the full story here. About ReShape Lifesciences Stock (OTCMKTS:RSLSD)ReShape Lifesciences Inc., a medical device company, focuses on the design, development, and commercialization of technology to treat obesity, metabolic diseases, and other gastrointestinal disorders. The company's product portfolio includes ReShape vBloc, a therapy that enables patients to feel full and eat less by intermittently blocking hunger signals on the vagus nerve; ReShape Vest system, an investigational, minimally invasive, laparoscopically implanted medical device that wraps around the stomach to enable weight loss in obese and morbidly obese patients without permanently changing patient anatomy; and Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in October 2017. ReShape Lifesciences Inc. was founded in 2002 and is headquartered in San Clemente, California.Read More RSLSD Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RSLSD Stock News HeadlinesSeptember 21, 2023 | finanznachrichten.deReShape Lifesciences Inc: ReShape Lifesciences Signs Exclusive License Agreement With Biorad Medisys for Obalon Gastric Balloon SystemSeptember 21, 2023 | finance.yahoo.comReShape Lifesciences® Signs Exclusive License Agreement With Biorad Medisys for Obalon® Gastric Balloon SystemApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."June 26, 2023 | finance.yahoo.comReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0June 14, 2023 | finance.yahoo.comReShape Lifesciences® to Participate in Investor and Industry Conferences in JuneMay 17, 2023 | insidermonkey.comReShape Lifesciences Inc. (NASDAQ:RSLS) Q1 2023 Earnings Call TranscriptApril 20, 2023 | finance.yahoo.comReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-MarketApril 12, 2023 | marketwatch.comReShape Lifesciences(R) Receives Notice of Allowance for U.S. Patent Related to its Obalon(R) Balloon SystemApril 24, 2024 | Stansberry Research (Ad)How to camouflage a factory of 53,000 workers"If I Had To Pour Every Single Penny of My Retirement Into Just ONE STOCK..." The former Goldman Sachs VP – who called everything from Microsoft's 1,100% surge... to the death of the 60/40 portfolio – is now stepping forward with his most explicit message yet: "Make this ONE STOCK the cornerstone of your portfolio."April 11, 2023 | finance.yahoo.comReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon SystemMarch 31, 2023 | seekingalpha.comReShape Lifesciences postpones earnings releaseMarch 28, 2023 | msn.comEarnings Outlook For Reshape LifesciencesFebruary 8, 2023 | benzinga.comReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public OfferingFebruary 3, 2023 | msn.comWhy Is Reshape Lifesciences (RSLS) Stock Up 136% Today?November 14, 2022 | seekingalpha.comReShape Lifesciences Inc. (RSLS) Q3 2022 Earnings Call TranscriptNovember 14, 2022 | yahoo.comReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateNovember 2, 2022 | benzinga.comReShape Lifesciences to Present at the Q4 Investor SummitSeptember 24, 2022 | stockhouse.comReShape Lifesciences(TM) Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation(TM) DeviceSeptember 22, 2022 | nz.finance.yahoo.comReShape Lifesciences™ Awarded Phase I NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ DeviceSeptember 14, 2022 | nz.finance.yahoo.comReShape Lifesciences Announces Participation in the A.G.P Virtual MedTech ConferenceSeptember 9, 2022 | msn.comReshape Lifesciences's Return On Capital Employed OverviewAugust 23, 2022 | finance.yahoo.comReShape Lifesciences Appoints Seasoned Sales and Marketing Executive, Nick Ansari, as Senior Vice President of Global Commercial OperationsAugust 16, 2022 | seekingalpha.comReShape Lifesciences Inc. (RSLS) CEO Paul Hickey on Q2 2022 Results - Earnings Call TranscriptAugust 16, 2022 | finance.yahoo.comReShape Lifesciences™ Reports Second Quarter 2022 Financial Results and Provides Corporate UpdateAugust 12, 2022 | msn.comReshape Lifesciences Earnings OutlookAugust 10, 2022 | nz.finance.yahoo.comReShape Lifesciences™ Receives FDA 510(k) Clearance for the GIBI HD™ Calibration Tubes for use in Gastric and Bariatric ProceduresJune 17, 2022 | finance.yahoo.comReShape Lifesciences Enters into Warrant Exercise Transaction for $2.5 Million in Gross ProceedsSee More Headlines Receive RSLSD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ReShape Lifesciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry N/A Sub-IndustryN/A Current SymbolOTCMKTS:RSLSD CUSIPN/A CIKN/A Webwww.reshapelifesciences.com Phone949-429-6680FaxN/AEmployees43Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-81,150,000.00 Net Margins-668.58% Pretax MarginN/A Return on Equity-163.22% Return on Assets-52.10% Debt Debt-to-Equity Ratio0.05 Current Ratio1.17 Quick Ratio1.07 Sales & Book Value Annual Sales$610,000.00 Price / Sales3.12 Cash Flow$67.13 per share Price / Cash Flow0.08 Book Value$341.84 per share Price / Book0.02Miscellaneous Outstanding Shares354,000Free FloatN/AMarket Cap$1.90 million OptionableNot Optionable Beta2.03 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Barton P. Bandy (Age 58)Pres, CEO & Director Dr. Mark B. Knudson (Age 70)Co-Founder and Special Advisor to the CEO Dr. Katherine S. Tweden Ph.D. (Age 58)Co-Founder Mr. Thomas Stankovich (Age 58)Chief Financial Officer Mr. Vipul ShahSr. VP of Operations and R&DKey CompetitorsStageZero Life SciencesOTCMKTS:GNWSDLucy Scientific DiscoveryNASDAQ:LSDINuwellisNASDAQ:NUWEQualigen TherapeuticsNASDAQ:QLGNGalmed PharmaceuticalsNASDAQ:GLMDView All Competitors RSLSD Stock Analysis - Frequently Asked Questions How have RSLSD shares performed in 2024? ReShape Lifesciences' stock was trading at $5.37 at the beginning of the year. Since then, RSLSD stock has increased by 0.0% and is now trading at $5.37. View the best growth stocks for 2024 here. How do I buy shares of ReShape Lifesciences? Shares of RSLSD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:RSLSD) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThis Apple-like Innovator is Revolutionizing HealthcareWall Street Startop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingThe Greatest Bull Market in Crypto History…Weiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ReShape Lifesciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
